Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Patent Action Today
View:
Post by Pandora on Apr 04, 2023 5:52pm

Patent Action Today

The below listed patent application was rejected by the USPTO on January 4, 2023.
The USPTO has now posted the Company's response to that non-final rejection.
Claim 1 is amended, Claims 18 - 22 are cancelled and Claims 23 - 27 are now added.
A lot of the rejection is tied to "failing to comply with the written description requirement".
The cancelled claims (18 - 22) are for an improper grouping of alternatives.
The claims have to do with the methods of using TLD1433 & TLD1824.
The modifications appear moderate but even so the USPTO now has up to 90 days
to say whether they accept them or not.

17/192,569 | T1081/20043:

SONODYNAMIC THERAPY USING SONODYNAMICALLY ACTIVATED COORDINATION COMPLEXES OF TRANSITION METALS AS SENSITIZING AGENTS

Public view
Application #

17/192,569

Confirmation #

5826

Attorney Docket #

T1081/20043

Patent #

-

Filing or 371 (c) date

03/04/2021

Status

Non Final Action Mailed 12/30/2022

Application data

Application type

Utility

Examiner

SAGAR S PATEL

 
Group art unit

1626

Class/subclass

514/492.000

AIA (first inventor to file)

Yes

Entity status

Small

Earliest publication #

US 2022-0296709 A1open_in_new

Earliest publication date

09/22/2022

Assignee for publication
-
Confirmation #
5826
Intl. registration # (Hague)

-

Intl. registration publication date

-

Correspondence address
3000 - CAESAR RIVISE, PC
 
7 Penn Center, 12th Floor
1635 Market Street
PhiladelphiaPA
UNITED STATES
Inventors
  • Arkady Mandel
    North York (CA)
  • Roger Dumoulin-White
    Toronto (CA)
  •  
Applicants
Theralase Technologies, Inc.
Toronto (CA)

Documents & transaction history

 
 
Showing 1 to 22 of 22 entries
 
 
Comment by O12009 on Apr 04, 2023 6:10pm
TLD 1824 i don't recall hearing about this compound  1633 was talked about 
Comment by Eoganacht on Apr 04, 2023 6:27pm
In 2017 they were talking about Osmium-based compounds TLD1822, TLD1824 and TLD1829. They picked TLD1829 as the best of the 3 to use against colon cancer. https://pubmed.ncbi.nlm.nih.gov/28370264/
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250